Best treatment for melasma: a layered, evidence-based plan.

Melasma does not "go away." It quiets, recurs, and — if you treat it the wrong way — gets worse than where you started. That is the unromantic frame every honest dermatologist uses when a new patient walks in asking for the "best treatment for melasma." There is no single best. There is a layered plan, tuned to your Fitzpatrick type, depth (epidermal, dermal, or mixed), hormonal exposure, and how much downtime your skin will actually tolerate. Get the layers in the right order and most people see meaningful, sustained improvement. Skip the boring foundation and chase a laser instead, and you will spend a year undoing the rebound.

This guide walks the evidence in the order a thoughtful clinician would build the plan: photoprotection first, then prescription topicals, then oral tranexamic acid for the right candidates, then — and only then — procedures. We will also be specific about what makes melasma worse, because that list is shorter, cheaper, and arguably more important than anything you add.

What melasma actually is, and why "best" is conditional

Melasma is an acquired hyperpigmentation driven by hyperactive melanocytes that are unusually sensitive to UV, visible light, heat, and hormonal stimulation. Histologically it sits in three patterns: epidermal (responds best to topicals), dermal (stubborn, deep brown-gray, often requires combined approaches), and mixed. Most adult facial melasma is mixed. That matters because the deeper the pigment, the less a surface-acting cream will ever do alone, and the more important sun and heat discipline becomes.

Two clinical facts shape every recommendation below. First, recurrence is the rule: even after near-complete clearance, pigmentation typically returns within months if photoprotection lapses or hormonal triggers continue. Second, melasma is an inflammatory and vascular disorder, not just a pigment problem — which is why anti-inflammatory and anti-angiogenic agents (azelaic acid, tranexamic acid) keep outperforming pure tyrosinase inhibitors in long-term studies.

Tier 1: do this first (and never stop)

Before any prescription, every melasma plan rests on three boring habits. Skip them and nothing else works.

Strict broad-spectrum SPF 50+, every day, with visible-light protection

UV is the obvious trigger, but high-energy visible light (HEVL) — the blue-violet end of daylight, including what comes through windows and off screens — induces pigmentation in skin of color independently of UV. This is the single most underappreciated point in melasma care. A standard mineral or chemical SPF 50 attenuates UV but does very little against visible light. The fix is iron oxides: tinted sunscreens containing iron oxides have demonstrated visible-light attenuation rates above 90% in clinical studies, and trials in melasma patients show meaningfully lower MASI scores at six months compared with non-tinted SPF of the same UV protection (JDD, 2020).

Practical rule: a daily, tinted, broad-spectrum SPF 50+ with iron oxides, reapplied every two hours of meaningful sun exposure, plus a wide-brimmed hat. If your current sunscreen is white and untinted, you are not protecting against the wavelengths that matter most for your condition.

Remove the heat and hormonal triggers you can

Heat alone activates melanocytes. Saunas, hot yoga, steam rooms, standing over a stove, even a long hot shower on the face — all documented melasma flares in clinic. You do not need to live like a vampire, but for the active treatment phase, treat your face like it is photoallergic. Cool water, cool environments, and a fan when you cook.

Hormonal exposure is the harder conversation. Combined oral contraceptives, hormone replacement therapy, and pregnancy ("chloasma") are the most consistent endogenous triggers. If your melasma started or worsened after starting OCPs, switching to a non-hormonal contraceptive or a progestin-only option (with your prescriber) often unmasks how much of the pigmentation is hormonally driven. The AAD patient guidance is explicit about this trigger pattern.

Gentle, anti-inflammatory routine

Melasma skin is irritable. Aggressive exfoliation, harsh acids stacked daily, retinoid burns, and abrasive cleansers all create post-inflammatory hyperpigmentation that compounds the underlying melasma. The Tier 1 routine is a bland gentle cleanser, a barrier-supporting moisturizer (ceramides, niacinamide), and the tinted SPF above. Save the actives for Tier 2 — under guidance, not stacked from your shopping cart.

Tier 2: add when Tier 1 plateaus (the working topicals)

Once sun and heat are controlled, topicals do most of the heavy lifting for epidermal and mixed melasma.

Hydroquinone 4% (prescription) — still the gold standard, with caveats

Hydroquinone (HQ) remains the most studied depigmenting agent in dermatology. The standard prescription strength is 4%, used short-term, typically as part of a triple combination cream (see below). It works by inhibiting tyrosinase, the rate-limiting enzyme in melanin synthesis.

The controversies are real but manageable. Exogenous ochronosis — a paradoxical blue-black discoloration that is largely permanent — is a documented complication. A systematic review found a median duration of HQ use of about five years before ochronosis appeared; cases under three months are vanishingly rare (PMC, exogenous ochronosis case review). The practical takeaway is not "avoid HQ" but "use it as a course, not a lifestyle": 8–16 weeks on, then pulse off or rotate to a non-HQ agent.

The Kligman triple cream — Tri-Luma (hydroquinone 4% + tretinoin 0.05% + fluocinolone 0.01%)

The only FDA-approved prescription for moderate-to-severe facial melasma is Tri-Luma, the modern descendant of the Kligman formula. In the pivotal trials referenced in the FDA label, about 77% of patients achieved complete or near-complete clearing by week 8. The label authorizes short-term use — eight weeks — explicitly because of the topical steroid component, which can cause atrophy and telangiectasia with prolonged daily application.

In practice, Tri-Luma is often used in cycles: nightly for 8 weeks, then de-escalated to a non-steroid maintenance topical, with cycles repeated if needed. Pair it with the photoprotection above; the label specifically requires it.

Cysteamine 5% (Cyspera) — the leading non-HQ option

Cysteamine is an endogenous aminothiol that depigments via multiple pathways and, unlike hydroquinone, is not associated with ochronosis. Head-to-head trials show comparable but slightly slower efficacy than 4% HQ — in one 16-week randomized study, MASI dropped about 64% with HQ versus 41% with cysteamine, with cysteamine remaining safe for long-term use (PubMed, cysteamine vs hydroquinone RCT). It is the practical answer to "what do I rotate to after my HQ course?" and a reasonable first-line for patients who want to avoid HQ entirely. The smell (it is a thiol) and short contact protocol (15 minutes, washed off) are the main adherence hurdles.

Topical tranexamic acid

TXA is a plasmin inhibitor that reduces UV-induced melanogenesis and dampens the vascular component of melasma. Topical formulations (typically 3–5%) are well tolerated and pair well with HQ or cysteamine. They are not as potent as oral TXA but carry no systemic risk, making them a useful daytime layer in maintenance phases.

Azelaic acid 15–20%

Often underrated. Azelaic acid is anti-inflammatory, mildly antibacterial, and a competitive tyrosinase inhibitor. It is safe in pregnancy (a rare property among melasma agents — relevant for chloasma), well tolerated in skin of color, and works synergistically with tranexamic acid or low-dose retinoids. The 20% prescription strength outperforms over-the-counter 10%; the 15% gel (sold for rosacea) is a practical middle ground.

Kojic acid and alpha-arbutin (OTC supports)

Kojic acid (1–4%) and alpha-arbutin (1–2%) are tyrosinase inhibitors that are useful as adjuncts but should not be expected to deliver dramatic monotherapy results. Their value is in the maintenance phase, layered with SPF, after the prescription agents have done the heavy lifting.

Tier 2.5: oral tranexamic acid — the quiet workhorse

Oral TXA has moved, over the past decade, from off-label curiosity to a mainstream second-line agent. The 2024 systematic review and meta-analysis of 22 RCTs (1,280 patients) found oral TXA produced the largest MASI reductions among TXA modalities, with the oral route outperforming topical and intradermal delivery (Tandfonline, 2024 meta-analysis; PubMed listing).

Dose: The standard melasma dose is 250 mg twice daily (BID), occasionally escalated to 500 mg BID for non-responders. This is far below the hemostatic dose used for menorrhagia. Initial course is typically 12–16 weeks; many clinicians taper rather than abrupt-stop to reduce rebound.

Who should not take it: TXA is antifibrinolytic. Absolute and relative contraindications include personal or family history of venous thromboembolism, active clotting disorder, current smoking (especially over age 35), concurrent combined hormonal contraception, recent surgery or immobility, and severe renal impairment (Mayo Clinic, oral tranexamic acid; StatPearls, NCBI). Every candidate needs a focused thrombotic-risk history before the first prescription. For a patient on a combined OCP who smokes, this is a hard no; for a 28-year-old non-smoker on a progestin-only IUD, it is usually fine with informed consent.

Honest framing for patients: Oral TXA is not "stronger" than topicals — it is complementary. It works particularly well in patients whose melasma has a strong vascular component (visible telangiectasias within the patches under polarized light), and in patients whose pigmentation rebounds rapidly with sun exposure despite good adherence to topicals. Recurrence after stopping is common; the gain is in clearing the active phase faster and more durably than topicals alone.

Tier 3: procedures — specialist territory only

Procedures are where most melasma plans go wrong. The temptation is to "zap" the pigment with a laser, and the consequence — in the wrong device, fluence, or skin type — is rebound hyperpigmentation that is harder to treat than the original disease. The conservative rule: procedures are added on top of well-controlled topicals, not in place of them.

Superficial chemical peels (the safest procedural layer)

Low-depth peels — 20–35% glycolic acid, mandelic acid 20–40%, Jessner's solution, lactic acid — produce gradual, controlled pigment turnover with minimal inflammation when performed in series (every 2–4 weeks, 4–6 sessions). For Fitzpatrick IV–VI, mandelic and lactic peels are generally preferred over glycolic, as their larger molecular size yields slower, more uniform penetration and lower post-inflammatory hyperpigmentation (PIH) risk (PMC, chemical peels for melasma in dark-skinned patients). Medium-depth and TCA peels are generally avoided in skin of color with melasma.

Microneedling (mechanical, not energy-based)

Conventional microneedling at conservative depths (0.5–1.0 mm) can enhance delivery of topical TXA or other depigmenting agents and is well tolerated across Fitzpatrick types. Evidence is modest but consistent; the main risk is over-treatment leading to PIH.

Sylfirm X (pulsed-wave non-insulated RF microneedling) — the procedural device with the strongest melasma evidence

Sylfirm X uses a pulsed-wave radiofrequency mode designed to target dysfunctional melanocytes and abnormal sub-basement-membrane vasculature without delivering the broad thermal injury that triggers melasma rebound. A 2022 split-face randomized trial in Fitzpatrick III–V patients showed significant mMASI reduction at six months across three biweekly sessions, with histologic evidence of reduced abnormal vasculature and melanin density (PMC, pulsed-wave RF microneedling for melasma). It is currently the procedural modality with the most favorable risk-benefit profile in mixed and dermal melasma, particularly in skin of color. It is not magic — it is an adjunct on top of Tiers 1–2 — but it is the best evidence-based procedural option for patients who have plateaued on topicals.

Q-switched and picosecond lasers at low fluence (controversial)

Low-fluence Q-switched 1064 nm "laser toning" and low-fluence picosecond protocols have published efficacy for melasma but a substantial rebound rate. The consensus across the PMC laser review and current expert opinion is that these should be reserved for refractory cases in experienced hands, at carefully titrated fluences, and never as first-line. The line between "improved" and "worse" with these devices is operator-dependent.

What makes melasma worse — the list to actually internalize

The procedural and lifestyle interventions that reliably worsen melasma:

• IPL (intense pulsed light) — improves short-term, then frequently rebounds within three months; thermal spillover is the mechanism. Largely contraindicated as a primary melasma treatment, particularly in Fitzpatrick III+ (PMC, lasers in melasma consensus).
• Fractional ablative lasers (CO2, Er:YAG) — high inflammatory load, well-documented rebound and post-inflammatory hyper- or hypopigmentation in skin of color.
• High-energy Q-switched or picosecond lasers at standard fluences — same problem, less downtime, similar rebound.
• Aggressive at-home routines — daily strong acids, daily retinoid stacking without titration, abrasive scrubs.
• Waxing, threading, depilatory inflammation on melasma-prone areas (upper lip, jawline) — friction and inflammation drive recurrence in exactly the cosmetic units patients most want to clear.
• Heat exposure — saunas, hot yoga, prolonged cooking over open flame, steamy showers on the face.
• Heavy occlusive skincare that traps heat or causes acneiform inflammation.

This list is not a moral judgment; it is a clinical pattern. If your melasma is not responding, audit this list before you escalate the prescription.

The tiered plan, condensed

Realistic expectations

A well-built plan typically delivers visible improvement at 8–12 weeks and substantial improvement at 4–6 months. "Substantial" usually means 50–75% reduction in MASI score — not full clearance — and the patients who hold their gains are the ones who stay on Tier 1 (sun, heat, hormones) and a low-intensity maintenance topical indefinitely. Patients who treat melasma as an event ("clear it and move on") almost universally recur within a year.

The honest answer to "what is the best treatment for melasma" is: the foundation you actually maintain, the prescription you cycle correctly, the systemic you add when warranted, and the procedures you do not do. In that order.

Sources

• American Academy of Dermatology. Melasma: Diagnosis and treatment.
• American Academy of Dermatology. Melasma: Causes.
• U.S. Food and Drug Administration. TRI-LUMA Cream (fluocinolone acetonide 0.01% / hydroquinone 4% / tretinoin 0.05%) — full prescribing information.
• DailyMed (NLM). TRI-LUMA cream label.
• Sarkar R, et al. Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials. J Dermatolog Treat, 2024.
• Tandfonline / PubMed listing. Tranexamic acid meta-analysis (2024).
• PMC / NIH. An Update on New and Existing Treatments for the Management of Melasma.
• PMC / NIH. Update on Melasma Treatments.
• PMC / NIH. Melasma: A Step-by-Step Approach Towards a Multimodal Combination Therapy.
• PMC / NIH. Lasers in Melasma: A Review with Consensus Recommendations by Indian Pigmentary Expert Group.
• PMC / NIH. Chemical Peels for Melasma in Dark-Skinned Patients.
• PMC / NIH. Efficacy and Safety of Pulsed-Type Noninsulated Microneedle RF for Melasma (split-face RCT).
• PMC / NIH. Exogenous Ochronosis After Prolonged Use of Topical Hydroquinone.
• PubMed. Evaluation of cysteamine cream compared to hydroquinone in the treatment of melasma: randomised, double-blinded trial.
• NCBI Bookshelf. Melasma — StatPearls.
• NCBI Bookshelf. Tranexamic Acid — StatPearls.
• Mayo Clinic. Tranexamic acid (oral route): side effects, contraindications, dosing.
• Journal of Drugs in Dermatology. Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals.
• American Society for Dermatologic Surgery. Chemical peels — procedure overview.
• American Society of Plastic Surgeons. Skin pigmentation disorders — patient information.